| Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data MWHL van Bennekom, J IntHout, HJ Gijsman, BBK Akdede, ... Schizophrenia Research 272, 1-11, 2024 | | 2024 |
| Die Rolle von Phytotherapie bei COVID-19-assoziierter Angst und Depression J Zourek, R Stange, S Kasper, L Bartova Zeitschrift für Phytotherapie 45 (04), 148-156, 2024 | | 2024 |
| The clinical perspective on late-onset depression in European real-world treatment settings L Bartova, G Fugger, M Dold, A Kautzky, I Bairhuber, P Kloimstein, ... European Neuropsychopharmacology 84, 59-68, 2024 | | 2024 |
| Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy P Baldinger-Melich, M Spies, I Bozic, S Kasper, D Rujescu, R Frey Wiener klinische Wochenschrift, 1-14, 2024 | | 2024 |
| Efficacy of Silexan in Patients with a Major Depressive Episode–First Results from a Multi-centre, Double-blind, Randomised, Placebo-and Reference-controlled Phase III Trial S Kasper, E Seifritz, HP Volz European Psychiatry 67 (S1), S224-S225, 2024 | | 2024 |
| Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo-and reference-controlled trial S Kasper, HP Volz, HJ Möller, S Schläfke, S Klement, IG Anghelescu, ... European Archives of Psychiatry and Clinical Neuroscience, 1-11, 2024 | 1 | 2024 |
| The impact of body mass index on the clinical features of bipolar disorder: A STEP‐BD study B Kadriu, ZD Deng, C Kraus, JN Johnston, A Fijtman, ID Henter, S Kasper, ... Bipolar Disorders 26 (2), 160-175, 2024 | 3 | 2024 |
| Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials M Dold, HJ Möller, HP Volz, E Seifritz, S Schläfke, L Bartova, S Kasper European Psychiatry 67 (1), e23, 2024 | 3 | 2024 |
| Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression V Oliva, A Martone, G Fanelli, K Domschke, A Minelli, M Gennarelli, ... Neuroscience Applied 3, 103937, 2024 | | 2024 |
| Revisiting benzodiazepines (GABA Enhancers): a transdiagnostic and precision medicine approach S Pallanti, J Zohar, S Kasper, HJ Möller, E Hollander Journal of Psychiatric Research, 2023 | 2 | 2023 |
| Overcoming the myths of esketamine administration: different and not difficult F Buchmayer, S Kasper Frontiers in Psychiatry 14, 1279657, 2023 | 6 | 2023 |
| Cheers and a thank-you note from the founding chief-editor S Kasper International Journal of Psychiatry in Clinical Practice 27 (4), 319-322, 2023 | | 2023 |
| Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions RS McIntyre, M Alsuwaidan, BT Baune, M Berk, K Demyttenaere, ... World Psychiatry 22 (3), 394-412, 2023 | 152 | 2023 |
| Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials M Dold, L Bartova, HP Volz, E Seifritz, HJ Möller, S Schläfke, S Kasper European Archives of Psychiatry and Clinical Neuroscience 273 (7), 1615-1628, 2023 | 10 | 2023 |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders H Himmerich, YD Lewis, C Conti, H Mutwalli, A Karwautz, JM Sjögren, ... The World Journal of Biological Psychiatry 24 (8), 643-706, 2023 | 44 | 2023 |
| Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan S Kasper, A Eckert, HJ Möller, HP Volz, E Seifritz International Journal of Psychiatry in Clinical Practice 27 (3), 285-291, 2023 | 4 | 2023 |
| Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database C Kraus, A Kautzky, V Watzal, A Gramser, B Kadriu, ZD Deng, L Bartova, ... Journal of affective disorders 335, 349-357, 2023 | 16 | 2023 |
| Reply to:“The serotonin theory of depression: a systematic umbrella review of the evidence” published by Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP … L Bartova, R Lanzenberger, D Rujescu, S Kasper Molecular Psychiatry 28 (8), 3153-3154, 2023 | 7 | 2023 |
| Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder L Bartova, G Fugger, M Dold, A Kautzky, G Fanelli, R Zanardi, D Albani, ... Journal of affective disorders 332, 105-114, 2023 | 2 | 2023 |
| General Principles of Pharmacologic Therapy K Inada, S Yamawaki, S Kanba, G Shinozaki, S Kasper Tasman’s Psychiatry, 1-18, 2023 | | 2023 |
Rupert LanzenbergerMedical University of Vienna在 meduniwien.ac.at 的电子邮件经过验证
